MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Sprache: | English |
| Veröffentlicht: |
Elsevier
2022
|
| _version_ | 1826310917600575488 |
|---|---|
| author | Sallman, D Malki, MA Asch, A Wang, E Jurcic, J Bradley, T Flinn, I Pollyea, D Kambhampati, S Tanaka, T Zeidner, J Garcia-Manero, G Jeyakumar, D Gu, L Tan, A Chao, M O'Hear, C Lal, I Vyas, P Daver, N |
| author_facet | Sallman, D Malki, MA Asch, A Wang, E Jurcic, J Bradley, T Flinn, I Pollyea, D Kambhampati, S Tanaka, T Zeidner, J Garcia-Manero, G Jeyakumar, D Gu, L Tan, A Chao, M O'Hear, C Lal, I Vyas, P Daver, N |
| author_sort | Sallman, D |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T08:00:35Z |
| format | Conference item |
| id | oxford-uuid:802e5581-3811-4b5f-a984-df0f254ccaf1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:00:35Z |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:802e5581-3811-4b5f-a984-df0f254ccaf12023-09-25T12:31:47ZMDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study resultsConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:802e5581-3811-4b5f-a984-df0f254ccaf1EnglishSymplectic ElementsElsevier2022Sallman, DMalki, MAAsch, AWang, EJurcic, JBradley, TFlinn, IPollyea, DKambhampati, STanaka, TZeidner, JGarcia-Manero, GJeyakumar, DGu, LTan, AChao, MO'Hear, CLal, IVyas, PDaver, N |
| spellingShingle | Sallman, D Malki, MA Asch, A Wang, E Jurcic, J Bradley, T Flinn, I Pollyea, D Kambhampati, S Tanaka, T Zeidner, J Garcia-Manero, G Jeyakumar, D Gu, L Tan, A Chao, M O'Hear, C Lal, I Vyas, P Daver, N MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results |
| title | MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results |
| title_full | MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results |
| title_fullStr | MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results |
| title_full_unstemmed | MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results |
| title_short | MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results |
| title_sort | mds 445 magrolimab in combination with azacitidine for patients with untreated higher risk myelodysplastic syndromes hr mds 5f9005 phase 1b study results |
| work_keys_str_mv | AT sallmand mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT malkima mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT ascha mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT wange mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT jurcicj mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT bradleyt mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT flinni mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT pollyead mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT kambhampatis mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT tanakat mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT zeidnerj mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT garciamanerog mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT jeyakumard mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT gul mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT tana mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT chaom mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT ohearc mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT lali mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT vyasp mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults AT davern mds445magrolimabincombinationwithazacitidineforpatientswithuntreatedhigherriskmyelodysplasticsyndromeshrmds5f9005phase1bstudyresults |